Beefing up its respiratory pipeline, GlaxoSmithKline bags J&J drug in $230M deal
GlaxoSmithKline has found a new therapy to add to its big pipeline of respiratory drugs. The UK-based pharma group in-licensed J&J’s CNTO 7160, an anti-IL-33R monoclonal antibody now in Phase I. J&J stands to get $230 million in an upfront plus a slate of milestones, which weren’t broken out in the statement.
The drug blocks interleukin-33 from binding to the ST2 receptor, a biologic step that plays a role with inflammatory cells like neutrophils and eosinophils, a big focus in asthma, which GSK has centered on for years now.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
